ALSO NOTED: Rebif gets EU nod; Bayer buys Citracal;

> Merck Serono got the EU nod to market a new version of the relapsing multiple sclerosis med Rebif. The new formulation, designed to be better tolerated when injected, will launch next month; the company is authorized to sell it in all 27 E.U. countries, plus Iceland, Liechtenstein and Norway. Release

> Bayer is buying the over-the-counter calcium supplement Citracal from Mission Pharmacal. The financial terms weren't disclosed, but the product sold some $47 million last year. Report

> Roche lost its bid to overturn an Australian ban on advertising the weight-loss drug Xenical. Report

> Contract manufacturer Catalent Pharma has signed a deal to increase production of Danish drug maker ALK-Abelló's tablet-based allergy vaccine Grazax, using a newly built production line funded by the drug company. Report

And Finally... Why aren't markets moved by government investigations of Big Pharma shenanigans? The Financial Times wants to know--especially when almost every major drug maker is under scrutiny, and a few have even pleaded guilty to corporate criminal charges. Report (sub. req.)

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.